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Adult pleomorphic rhabdomyosarcoma (RMS) is a rare and malignant mesenchymal tumor. Recently, we
developed a patient-derived orthotopic xenograft (PDOX) model of adult pleomorphic RMS. In the present study,
we evaluated the efficacy of tumor-targeting Salmonella typhimurium (S. typhimurium) A1-R combined with caffeine (CAF)
and valproic acid (VPA) on the adult RMS PDOX. An adult pleomorphic RMS cell line was established from the
PDOX model. Cell survival after exposure to CAF and VPA was assessed, and the IC50 value was calculated for
each drug. The RMS PDOX models were randomized into five groups: untreated control; tumor treated with
cyclophosphamide (CPA); tumor treated with CAFþ VPA; tumor treated with S. typhimurium A1-R; and tumor treated
with S. typhimurium A1-R þ CAF þ VPA. Tumor size and body weight was measured twice a week. VPA caused a
concentration-dependent cytocidal effect. A synergistic effect of combination treatment with CAF was observed
against the RMS cell line. For the in vivo study, all treatments significantly inhibited tumor growth compared with
the untreated control. S. typhimurium A1-R combined with VPA and CAF was significantly more effective than CPA,
VPA combined with CAF, or S. typhimurium A1-R alone and significantly regressed the tumor volume compared with
day 0. These results suggest that S. typhimurium A1-R together with VPA and CAF could regresses an adult
pleomorphic RMS in a PDOX model and therefore has important future clinical potential.
Translational Oncology (2020) 13, 393–400Introduction
Rhabdomyosarcoma (RMS) is a rare and highly malignant
mesenchymal tumor [1,2]. It is a common childhood cancer
comprising more than 50% of all pediatric soft tissue sarcomas
(STSs). In contrast, RMS is uncommon in adults and comprises <1%
of all adult malignancies. RMS accounts for 3% of all STS [3,4].
Histologically, RMSs are classified into three major subgroups:
embryonal RMS, pleomorphic RMS, and alveolar RMS. Pleomorphic
RMS and alveolar RMS have poor prognosis compared with
embryonal RMS [5,6].
Most RMSs are diagnosed in patients younger than 10 years old
and these patients have better outcomes compared with older patients
394 S. typhimurium A1-R, VPA and CAF combination Igarashi et al. Translational Oncology Vol. 13, No. 2, 2020[7e9]. Adult patients had poor prognosis, and overall survival (OS) at
5 years was <40% [5]. In contrast, 5-year OS for younger patients
was >60% [10]. However, for adult patients with metastatic disease,
the 5 year survival was <5% [11,12].
Adult RMS is a highly malignant tumor with a significant
incidence of metastatic recurrence [12]. Novel more effective
treatment is needed for adult RMS. RMS in the adult population
has a low incidence; therefore, the study of RMS in this group is
challenging. Clinically-relevant mouse models of RMS could permit
evaluation of tailor-made therapy based on the patient-derived tumor.
We have developed the patient-derived orthotopic xenograft (PDOX)
nude mouse model for all major cancers [13]. Recently, we have
reported a comparative study of PDOX nude mouse model and
subcutaneous xenografted model of adult pleomorphic RMS [14].
The behavior of the PDOX mouse model was more similar to the
patient tumor in growth and local aggressiveness.
Caffeine (CAF) (1,3,7-trimethylxanthine) is a natural stimulatory
compound and shown to be effective against tumors by inducing
apoptosis [15e17]. CAF can also overcome chemotherapy- or
radiation-induced delays in cell cycle progression [18,19], thereby
enhancing their efficacy [20].
Valproic acid (VPA), a short-chain fatty acid, is widely used to treat
epilepsy and has been reported to be a potent histone deacetylase
(HDAC) inhibitor. HDAC inhibitors can induce apoptosis, cell
differentiation, autophagy, and are anti-angiogenic [21]. VPA has
been used for treatment of myelodysplastic syndrome [22], melanoma
[23], and solid tumors [24]. We have reported the synergistic efficacy
of the combination of CAF and VPA for sarcomas [25].
The tumor-target ing Salmonel la typhimurium A1-R
(S. typhimurium A1-R), developed by our laboratory [26], is
auxotrophic for LeueArg, which prevents it from mounting a
continuous infection in normal tissues. S. typhimurium A1-R was
shown to be effective against primary and metastatic tumors in
PDOX models of major cancers [27e30].
In the present study, we evaluated the efficacy of S. typhimurium
A1-R alone and in combination with CAF and VPA on a PDOX
model of adult pleomorphic RMS.
Materials and Methods
Animal Care
Athymic nu/nu nude mice (AntiCancer Inc., San Diego, CA), 4- to
6-week old, were used in this study [14]. All animal studies were
conducted with an AntiCancer Inc., Institutional Animal Care and
Use Committee protocol specifically approved for this study and in
accordance with the principles and procedures outlined in the
National Institutes of Health Guide for the Care and Use of Animals
under Assurance Number A3873-1 [14]. Animal suffering was
avoided by using anesthesia and analgesics for all surgical experiments.
Detailed protocols of handling animals, feeding, anesthesia, injection,
and humane endpoint criteria were described in previous publication
[14].
Patient-Derived Tumor
A 68-year-old male diagnosed with pleomorphic RMS in a large
primary right-high-thigh tumor underwent surgical resection at the
Department of Surgery, University of California, Los Angeles
(UCLA). He did not receive any chemotherapy or radiotherapy
before surgery. Written informed consent was obtained from thepatient as part of a UCLA Institutional Review Board (IRB
#10-001857)-approved protocol [14]. Briefly, the subcutaneous
tumor was harvested and divided into 3-4mm3 fragments and one
fragment was inserted in the left biceps femoris muscle using the
technique of surgical orthotopic implantation (SOI) [14].Surgical Orthotopic Implantation for Establishment of PDOX
Model
Detailed protocols for obtaining a fresh sample of the tumor of the
patient, its transportation to the laboratory at AntiCancer Inc., tumor
fragmentation, subcutaneous implantation in nude mice, establishing
a PDOX model, and wound closure were previously described [14].Primary Culture of Patient-Derived Tumor
After the RMS was grown and established in nude mice, the grown
tumors were harvested and were cut into small fragments (1 mm or
less). Then fragments were placed in RPMI1640 supplemented with
10% fetal bovine serum (FBS) into a 25 cm2 sterile flask. The cell
culture was rinsed the next day with phosphate-buffered saline (PBS)
twice to remove nonadherent cells and excess tissue in the flask. The
medium was changed every 3e4 days thereafter.Growth Inhibition Assay
Cellular viability was assessed using the WST-8 dye reduction
assay. Cells were seeded in 96-well flat-bottomed microplates
(100 mL/well) at a 5  104 cells/mL density, incubated at 37 C
for 24 h, and exposed to various concentrations of tested compounds
for 72 h. For each concentration, at least 8 wells were used. After
incubation with the test compounds, 10 ml WST-8 solution was
added to each well. The microplates were further incubated for 3 h at
37 C, and absorption was measured using a microprocessor-con-
trolled microplate reader (SunriseTM; TECAN, San Joes, CA, USA)
at 450 nm. Cell-survival fractions were calculated as the percentage of
untreated control cells. IC50 values were derived from
concentrationeresponse curves.Calculation of Combination Index
The specific interaction between CAF and VPA on the RMS cell
lines was evaluated by the combination index (CI) assay using
CalcuSyn software from ComboSyn Inc. (New Jersey, USA), with the
method of Chou and Martin [31]. In this analysis, synergy was
defined as a CI < 1.0, antagonism as a CI > 1.0, and additivity as CI
values not significantly different from 1.0.Preparation and Administration of S. typhimurium A1-R
GFP-expressing S. typhimurium A1-R bacteria (AntiCancer Inc.,)
were grown overnight in LB medium (Fisher Sci., Hanover Park, IL,
USA) and then diluted 1:10 in LB medium. Bacteria were harvested
at late-log phase, washed with PBS, and then diluted in PBS.
S. typhimurium A1-R was injected intravenously. A total of
5  107 CFU S. typhimurium A1-R in 100 ml PBS was administered
to each mouse [30,32,33].Confocal Microscopy
The FV1000 confocal microscope (Olympus, Tokyo, Japan) was
used for high-resolution imaging. Fluorescence images were obtained
using the 20/0.50 UPlan FLN and 40/1.3 oil Olympus UPLAN
FLN objectives [34].
Table 1. IC50 Value of Valproic Acid Against Rhabdomyosarcoma Cells with and Without Adding
0.5 mM and 1 mM of Caffeine. AC-RMS01 Cells were incubated with each drug for 72 h and then
assessed via the WST-8 assay
VPA IC50 (mg/mL)
þCAF 0.5 mM þCAF 1 mM
AC-RMS01 353.6 ± 32.9 204.9 ± 20.2** 156.1 ± 23.7**
** p<0.001.
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RMS PDOX Mouse
Six PDOX mouse models were treated with S. typhimurium
A1-R-GFP (5  107 CFU/100 ml, i.v., once) when tumor volume
reached 500 mm3. The PDOX tumors and tibialis anterior muscle of
the affected limb were resected on day 1 and day 3 from three mice.
The distribution of S. typhimurium A1-R was accessed by confocal
imaging with the FV1000 [35]. Random three fields were accessed for
each specimen.
Treatment Study Design in the PDOX Model of Adult
Pleomorphic RMS
PDOX mouse models were randomized into four groups of eight
mice each when tumor volume reached 100 mm3: G1, control
without treatment; G2, treated with cyclophosphamide (CPA)
(140 mg/kg, intraperitoneal (i.p.) injection, weekly, for 3 weeks);
G3, treated with CAF (100 mg/kg, i.p., daily, for 3 weeks) combined
with VPA (500 mg/kg, i.p., daily for 3 weeks); G4, S. typhimurium
A1-R (5  107 CFU/100 ml, i.v., weekly, for 3 weeks); and G5,
S. typhimurium A1-R combined with CAF and VPA (5  107 CFU/
100 ml, i.v., weekly, for 3 weeks, 100 mg/kg, i.p., daily for 3 weeks
and 500 mg/kg, i.p., daily for 3 weeks, respectively). Tumor size and
body weight was measured with calipers and a digital balance twice a
week. Tumor length, width, and mouse body weight was measured
twice per week. Tumor volume was calculated by the following
formula: Tumor volume (mm3) ¼ length (mm)  width
(mm)  width (mm)  1/2. Data were presented as mean ± SD.
Results
In Vitro Combination Effect of CAF and VPA on Adult
Pleomorphic RMS Cell in Culture
The cytotoxic activity of CAF and VPA was determined in an adult
pleomorphic RMS cell line which was established from a patient--
derived xenograft. Cells were incubated for 72 h with each
compound. Cell survival was evaluated as described in the Materials
and Methods. To evaluate the potential combined effect of CAF and
VPA, the CI values were determined using the WST-8 assay.
Addition of 0.5 mM CAF in 1 mM VPA enhanced anti-proliferation0
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Figure 1. Effect of caffeine (CAF) and valproic acid (VPA) on
adult pleomorphic RMS cell in culture. Growth inhibitory activity
of CAF and VPA or their combination against an adult
pleomorphic rhabdomyosarcoma cell line AC-RMS01.activity against adult pleomorphic RMS cells (Figure 1, Table 1). In
addition, the CI values were significantly <1 which revealed synergy
at all explored concentrations in the adult pleomorphic RMS cell line
(Table 2). Thus, we found a synergistic effect for the combination of
CAF and VPA in the adult pleomorphic RMS cell line.
Tumor Targeting of S. typhimurium A1-R-GFP in an Adult
Pleomorphic RMS PDOX Mouse Model
Tumor targeting of S. typhimurium A1-R-GFP was demonstrated
by confocal imaging with the FV1000 on day 1 and day 3 after
intravenous injection of S. typhimurium A1-R-GFP (Figure 2). The
mean fluorescence intensity of S. typhimurium A1-R-GFP of the
PDOX tumor on day 1 and day 3 was 4.63  105 and 6.57  106,
respectively (P ¼ 0.017; Figure 3A). The fluorescence area of
S. typhimurium A1-R-GFP of the PDOX tumor on day 1 and day 3
was 23.2 ± 6.4 mm2 and 89.1 ± 27.0 mm2, respectively (P ¼ 0.045;
Figure 3B).
S. typhimurium A1-R-GFP was not detected by the FV1000 both
on day 1 and day 3 in the tibialis anterior muscle of affected limb
(Figures 2 and 3).
Effect of CPA, VPA, and CAF Combination with
S. typhimurium A1-R on the Adult Pleomorphic RMS PDOX
Mouse Model
On day 21 after initiation of treatment, mean tumor volume of
each group was measured: control (G1): 585.6 ± 193.1 mm3; CPA
(G2): 297.3 ± 48.6 mm3; VPA þ CAF (G3): 232.9 ± 43.9 mm3;
S. typhimurium A1-R (G4): 193.0 ± 46.4 mm3; S. typhimurium
A1-R combined with VPA and CAF (G5): 88.3 ± 29.1 mm3
(Figure 4A and B). All treatments significantly inhibited tumor
growth compared with the untreated control (Figure 4): (CPA:
P ¼ 0.0019; VPA combined with CAF: P ¼ 0.0005; S. typhimurium
A1-R: P ¼ 0.0002; S. typhimurium A1-R combined with VPA and
CAF: P < 0.0001). S. typhimurium A1-R combined with VPA and
CAF was significantly more effective than either CPA (P < 0.0001),
VPA combined with CAF (P < 0.0001) or S. typhimurium A1-R
alone (P < 0.0001) (Figure 4B). S. typhimurium A1-R combined with
VPA and CAF significantly regressed the tumor volume comparedTable 2. CI Value of Combination of Caffeine and Valproic Acid
Drug concentration CI Drug concentration CI
CAF VPA CAF VPA
0.5 50.0 0.69641 1.0 50.0 0.80347
0.5 100.0 0.75105 1.0 100.0 0.83614
0.5 250.0 0.84027 1.0 250.0 0.94098
0.5 500.0 0.84129 1.0 500.0 0.89964
0.5 1000.0 0.8963 1.0 1000.0 0.96722
The CI values were calculated in each combination ratio. The CI values of <1, 1, or >1 indicate
synergism, additively, and antagonism, respectively.
Figure 2. Fluorescence imaging of Salmonella typhimurium A1-R-GFP. Fluorescence confocal imaging of S. typhimurium A1-R-GFP
targeting the adult pleomorphic RMS PDOX. Bars: 12.5 μm.
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any group. The body weight of treated mice was not significantly
different in any group.
Histology
High-power photomicrographs of the original patient tumor
demonstrated solid sheets of cancer cells characterized by pleo-
morphic, hyperchromatic, enlarged nuclei with coarse chromatin and
moderate amounts of lightly eosinophilic cytoplasm. NumerousFigure 3. Fluorescence of Salmonella typhimurium A1-R-GFP ta
intensity of S. typhimurium A1-R-GFP on the adult pleomorphic RM
the adult pleomorphic RMS PDOX.mitotic figures, including atypical forms, are present (Figure 5A). A
high-power view of the orthotopically implanted tumor demonstrated
identical features including pleomorphic, hyperchromatic, enlarged
nuclei with coarse chromatin and moderate amounts of lightly
eosinophilic cytoplasm. Numerous mitotic figures, including atypical
forms, are also present. The histology of the -untreated PDOX tumor
closely matched the patient's tumor with the cells of both looking very
similar (Figure 5B), demonstrating the fidelity of the PDOX tumor.
Tumors treated with CPA comprised viable cells without apparentrgeting the adult pleomorphic RMS PDOX. (A) Fluorescence
S PDOX. (B) Fluorescence area of S. typhimurium A1-R-GFP on
Figure 4. (A) Treatment scheme. (B) Efficacy of cyclophosphamide (CPA), VPA combined with CAF, Salmonella typhimurium A1-R
(A1-R) and A1-R combined with VPA and CAF on the adult pleomorphic rhabdomyosarcoma PDOX. *P < 0.0001. Tumor volumewas
measured at the indicated time points after the onset of treatment. n ¼ 8 mice/group.
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CAF combined with VPA and treated with S. typhimurium A1-R
show changes in cancer cell shapes and reduced cellularity (Figure 5D
and E). Tumors treated with CAF combined with VPA and
S. typhimurium A1-R show apparent tumor necrosis with tissue
fibrosis (Figure 5F).Figure 5. Tumor histology. H & E-stained section of the original pa
with CPA (C); PDOX tumor treated with VPA combined with CAF (
and PDOX tumor treated with CAF combined with VPA and S. typDiscussion
Bone sarcomas and STS are rare and heterogeneous group of cancers
distinguished into more than 100 subtypes. Doxorubicin (DOX) and
cisplatinum (CDDP) are still the standard and most effective
therapeutics after four decades. For advanced sarcoma, patient
treatment outcomes are unsatisfactory. Clinical trials evaluating thetient tumor (A); untreated PDOX tumor (B); PDOX tumor treated
D); PDOX tumor treated with Salmonella typhimurium A1-R (E);
himurium A1-R (F). Scale bars: 80 μm.
398 S. typhimurium A1-R, VPA and CAF combination Igarashi et al. Translational Oncology Vol. 13, No. 2, 2020efficacy of novel systemic treatment including targeted and immune
therapy in sarcoma have been limited because of the rarity and
heterogeneity of these tumors.
The response rates of STSs to chemotherapy are relatively low
(20e30%). Patients who respond to systemic therapy have
significantly improved outcomes [35]. PDX models have provided
a way for more clinically-relevant individualized mouse models of
sarcoma that recapitulate local tumor behavior and mimic tumor--
specific drug sensitivity. However, subcutaneous models of cancer
rarely metastasize and few PDX models replicate advanced disease
states [13].
PDOX models of sarcoma behave quite similar to patient sarcoma
with regard to recurrence after surgery [14], metastasis [36], and
invasively grow to surrounding tissues [14]. These properties present
the opportunity to test multiple therapeutic agents [36e49],
including targeted therapy [38] and experimental therapy such as
novel platinum agents [43], and tumor-targeting S. typhimurium
A1-R [46e48] in a preclinical model, without the patient suffering
from the potential toxicity and morbidity of ineffective drugs. In the
present study, S. typhimurium A1-R combined with CAF and VPA
regressed an adult pleomorphic RMS PDOX model.
Cell cycle arrest is crucial for cell differentiation. p21 is a
cyclin-dependent kinase (CDK) inhibitor gene which is important
regulator of the cell cycle. VPA induces suppression of cyclineCDK
complexes through acetylation of histone H3 level in p21 promoter
and blockage of phosphorylation of retinoblastoma protein, resulting
in G0/G1 arrest [50e52]. S. typhimurium A1-R decoys quiescent
cancer cells in tumors from G0/G1 to S/G2/M phase with subsequent
apoptosis [53]. CAF may induce the apoptosis of cancer cells arrested
by S. typhimurium A1-R by inducing mitotic catastrophe [20]. The
histological data (Figure 5) show reduced cellularity in all treatment
groups with the greatest reduction in the group treatment with
S. typhimurium A1-R combined with CAF and VPA. These data are
consistent with the tumor regression in this group and indicate
extensive apoptosis. Future experiments will use specific apoptosis
markers and will test the individual and combined effect of these
interventions on apoptosis.
Conclusions
Our results suggest that S. typhimurium A1-R combined with VPA
and CAF could regress an adult pleomorphic RMS in a PDOX model
and therefore has important future clinical potential for patients.
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